Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

Evaluating the VeraBIND Tau Assay for Earlier Detection of Alzheimer Disease: John Forrest

by Neurology Live
0 Comments
0 Mins
At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]
Tags:
Neurology Live
Author

Neurology Live

Previous Post
Chemotherapy Alters DNA, Accelerates Aging in Healthy Cells
Next Post
FDA Grants Breakthrough Status to Melanoma Test
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago